	US 12,006,500 B2
	Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)
Danny Tang, Guangdong (CN); Xueping Chen, Guangdong (CN); Patrick Y. Lu, Potomac, MD (US); Vera Simonenko, Gaithersburg, MD (US); David Evans, Gaithersburg, MD (US); John Xu, Gaithersburg, MD (US); Deling Wang, Jiangsu (CN); and Alan Lu, Gaithersburg, MD (US)
Assigned to Sirnaomics, Inc., Germantown, MD (US)
Filed by Sirnaomics, Inc., Gaithersburg, MD (US)
Filed on Jan. 25, 2021, as Appl. No. 17/157,920.
Claims priority of provisional application 62/965,063, filed on Jan. 23, 2020.
Prior Publication US 2021/0246448 A1, Aug. 12, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 9/51 (2006.01); A61K 31/713 (2006.01); A61K 47/28 (2006.01); A61K 47/69 (2017.01); A61P 31/14 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 9/513 (2013.01); A61K 31/713 (2013.01); A61K 47/28 (2013.01); A61K 47/6931 (2017.08); A61P 31/14 (2018.01)]

16 Claims

1. A pharmaceutical composition comprising at least a first siRNA molecule that targets a conserved region of an ORF1AB gene of the Wuhan seafood market novel pneumonia 2019 Novel Coronavirus (2019-nCoV) genome, and at least a second siRNA that targets a conserved region of an N-protein gene of said 2019-nCoV genome, wherein said composition comprises a pharmaceutically acceptable carrier, wherein said carrier comprises a polymeric nanoparticle and/or a liposomal nanoparticle carrier, wherein said first siRNA molecule is selected from the group consisting of SEQ ID NO:401-403 and 414-418, and wherein said second siRNA molecule is selected from the group consisting of SEQ ID NO: 404-406 and 425-431.